Wail Asfour, MD
Cardiovascular Disease · Munster, INNPI 1720038680
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (32.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Medtronic at 46.1% of the total. Reporting peaked in 2024 at $23,201 and has fallen 78.6% since, to $4,965 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 798 payments — averaging $88.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$33K
- Bard Peripheral Vascular, Inc.$6K
- Philips North America LLC$5K
- Penumbra, Inc.$4K
- Abbott$4K
- Cordis US CORP.$3K
- plus $17K from 54 others
Across 230 payments — averaging $2894.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$367K
- Boehringer Ingelheim Pharma GmbH & Co.kg$247K
- Kowa Research Institute, Inc.$27K
- AstraZeneca$24K
- Abbott$950
What the payments were for
- Consulting fees$8,38312%
- Speaking & faculty fees$19,00027%
- Grants$550%
- Travel & lodging$19,81628%
- Food & beverage$23,26133%
- Education$410%
- Other$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Abre$17,923
- IN.PACT Admiral$9,276
- LUTONIX$4,200
- (9520) IGT Devices Undivided$3,440
- Indigo System$1,971
- Impella$1,760
- XACT$1,653
- HawkOne$1,503
- LifeVest$1,500
- RUBY Coil$1,384
- AngioJet Ultra 5000A$886
- Peripheral Orbital Atherectomy System$573
- Pounce Venous Thrombectomy System$546
- Sublime 014 Rx PTA Balloon Dilatation Catheter$546
- Auryon Laser System 100-120 Vac$482
- Pounce Thrombectomy System$423
- Sublime Radial Access 018 RX PTA Dilatation Catheter$345
- Sublime Radial Access Guide Sheath$345
- Pounce Thrombectomy$323
- COBALT DR MRI SURESCAN$321
How this compares
$70,635 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $316,615 |
| EntrestoSacubitril/Valsartan | 150 | $137,949 |
| XareltoRivaroxaban | 128 | $119,230 |
| FarxigaDapagliflozin Propanediol | 34 | $27,328 |
| JanuviaSitagliptin Phosphate | 11 | $18,804 |
| MultaqDronedarone Hcl | 12 | $9,740 |
| ClopidogrelClopidogrel Bisulfate | 646 | $5,952 |
| Atorvastatin Calcium | 455 | $3,673 |
| Amiodarone Hcl | 144 | $3,539 |
| Metoprolol Succinate | 231 | $3,035 |
| Esomeprazole Magnesium | 26 | $1,828 |
| Lisinopril | 213 | $1,628 |
| Potassium Chloride | 89 | $1,623 |
| Rosuvastatin Calcium | 109 | $1,512 |
| Metoprolol Tartrate | 285 | $1,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $316,615341 claims |
| NovartisEntresto | $1,659 | $137,949150 claims |
| Johnson & JohnsonXarelto | $511 | $119,230128 claims |
| AstraZenecaFarxiga | $165 | $27,32834 claims |
| MerckJanuvia | $91 | $18,80411 claims |
| Sanofi-aventis U.S. LLCMultaq | $179 | $9,74012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Munster
- Omar HusseiniMunster$66K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.